^
    Back
    Association details:
    Biomarker:ALK fusion
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Excerpt:
    All patients with nonsquamous NSCLC...alectinib or brigatinib is the optimal first-line treatment for patients with anaplastic lymphoma kinase fusions.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    Manufacturing and Marketing Approval Received in Japan for ALUNBRIG® in the Treatment of ALK Fusion Gene-positive Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer

    Excerpt:
    ...Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that it has obtained approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market “ALUNBRIG® Tablets 30 mg, 90 mg" (brigatinib, development code: AP26113) as a first and second-line therapy for the treatment of patients with unresectable, advanced or recurrent ALK fusion gene-positive non-small cell lung cancer (ALK+ NSCLC).